Efficacy and Safety of Polyoxidonium, Nasal and Sublingual Spray, 6 mg/ml in Children Aged 1-12 Years With ARI

Exclusion Criteria

• •Suspicion on pneumonia, bacterial infection (including meningitis, sepsis, otitis media, sinusitis, sinusitis, urinary tract infection etc.) or a condition that requires antibacterial therapy from the first day of treatment.
• •Suspicion on other diseases that may simulate acute respiratory viral infection at the moment of onset (other infectious diseases, flu-like syndrome in system collagen and other diseases).
• •Positive express test for influenza or streptococcal infection.
• •Clinical signs of serious acute respiratory viral infection, which requires hospitalization (fever ≥ 40°C, sings of airway obstruction, significant hemodynamic or neurological disorders).
• •History of primary or secondary immunodeficiency.
• •Cancer.
• •Acute infectious and non-infectious diseases (except acute respiratory viral infection), exacerbation or decompensation of chronic diseases (diabetes mellitus, infantile cerebral paralysis, cystic fibrosis, primary ciliary dyskinesia, bronchopulmonary dysplasia, malformations of upper respiratory tract,ears, nose, or throat) which may affect an ability of patient to participate in study.
• •Saccharase/isomaltase deficiency, fructose intolerance, glucose-galactose malabsorption.
• •History of allergy/hypersensitivity to any component of the study drug (including paracetamol, propacetamol hydrochloride).
• •Use of protocol-prohibited medications within 1 month prior to study.
• •Children, who's parents/adopters may fail to follow the protocol procedures and treatment, in investigator's opinion.
• •Participation in other studies within 3 months to screening.
• •Pregnancy.
• •Any other medical or social condition that may interrupt study participation, in investigator's opinion.